The latest price target for Mereo BioPharma Group (NASDAQ:MREO) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $7.00 expecting MREO to rise to within 12 months (a possible 64.71% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Mereo BioPharma Group (NASDAQ:MREO) was provided by Cantor Fitzgerald, and Mereo BioPharma Group reiterated their overweight rating.

There is no last upgrade for Mereo BioPharma Group

There is no last downgrade for Mereo BioPharma Group.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mereo BioPharma Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mereo BioPharma Group was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Mereo BioPharma Group (MREO) rating was a reiterated with a price target of $7.00 to $7.00. The current price Mereo BioPharma Group (MREO) is trading at is $4.25, which is out of the analyst’s predicted range.